Delivery Order SPE2DB24D1104-SPE2DB25FYFV6
- Not listed
- The Defense Logistics Agency awarded a $29,794.79 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on September 8, 2025, with completion targeted for September 9, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen,...
- The Defense Logistics Agency awarded a $155,792.11 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors, with an ultimate completion date of September 11, 2025. This non-set-aside competitive award was issued on September 10, 2025, with performance to be conducted at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract action under the company's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections (2 ml quantity) with a ceiling value of $21,486.82. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The order is set for ultimate completion by September 11, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $4,184.06 under firm fixed price terms. The order is scheduled for completion by September 10, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $53,305.92 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and has an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a delivery order, this award is a child contract executed under a larger...
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $61,412.92. This competitively awarded, non-set-aside contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of performance is located in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $18,029.12 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This non-set-aside, competitively awarded contract utilizes firm fixed price terms with an ultimate completion date of September 5, 2025. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- SPE2DB24D1104Indefinite Delivery Contract
- SPE2DB24D1104-SPE2DB25FYFV6Delivery Order
The Defense Logistics Agency awarded a $29,308.15 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, which is a non-set-aside competitive award, carries an ultimate completion date of September 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as the primary vehicle for pharmaceutical supply to military healthcare systems worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies a comprehensive range of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to support Defense Health Agency and military healthcare programs. As a competitive awardee with demonstrated capability to meet federal procurement requirements, the company has established a substantial portfolio of delivery orders across multiple therapeutic domains through its DLA contracts. This award for Dupixent—a biologic immunosuppressant used to treat conditions such as atopic dermatitis and eosinophilic asthma—continues the company's role as a key supplier of specialized pharmaceutical products for military medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $29.3k | 9/12/25 |